Trial Profile
An open-label, multicenter, pilot study of the safety and efficacy of transitioning from a stimulant medication to atomoxetine in pediatric and adolescent outpatients with DSM-IV attention-deficit/hyperactivity disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2007
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 20 Jun 2007 New trial record.